journal article·2021-06Open access

Imaging the cellular components of the immune system for advancing diagnosis and immunotherapy of cancers

K. Bhise, S. Sau, R. Alzhrani, M.A. Rauf, K. Tatiparti, A.K. Iyer

Abstract

Immunotherapy has gathered momentum in the advanced generation of cancer therapeutics. Many unresectable resistant tumor subtypes are ideal candidates for immunotherapy; however, the efficacy is limited because of heterogeneity of both malignant cells and non-malignant cells of the tumor microenvironment, including stromal and immune cells. The success of immunotherapy is largely dependent on the population of individual immune cell types between patients of the same tumor subtype, and the expression of biomarkers that are expressed by the components of the immune system. Hence, it is imperative to first identify the components of the immune system, visualize these populations in the tumor microenvironment, and then devise specifically targeted immunotherapies. In this review, we have outlined strategies to characterize the cellular components of the immune system with clinically relevant imaging modalities. The importance of high dimensional analyses including mass cytometry and unbiased single-cell RNA sequence analysis in visualizing the ideal candidates for immunotherapy has been discussed. This review stresses the importance of immuno-imaging as a means to further develop targeted immunotherapies for cancer.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Cancer Immunotherapy and Biomarkers · Immunotherapy and Immune Responses · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. In vivo imaging in cancer10.1101/cshperspect.a003848 ↗
2. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials10.1111/pcmr.12340 ↗
3. Tumor-infiltrating lymphocyte composition, organization and PD-1/PD-l1 expression are linked in breast cancer10.1080/2162402X.2016.1257452 ↗
4. Imaging biomarkers in immunotherapy
5. Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients?10.1200/EDBK_240837 ↗
6. Oncology meets immunology: the cancer-immunity cycle10.1016/j.immuni.2013.07.012 ↗
7. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations10.3389/fonc.2018.00086 ↗
8. Resistance to checkpoint inhibition in cancer immunotherapy10.1016/j.tranon.2019.12.010 ↗
9. Imaging of T-cells and their responses during anti-cancer immunotherapy10.7150/thno.37924 ↗
10. Monitoring immune-checkpoint blockade: response evaluation and biomarker development10.1038/nrclinonc.2017.88 ↗
11. Nuclear magnetic resonance imaging and evaluation of human breast tissue: preliminary clinical trials10.1148/radiology.143.1.7063727 ↗
12. Imaging and cancer: a review10.1016/j.molonc.2008.04.001 ↗
13. Gadolinium-based contrast agents for magnetic resonance cancer imaging
14. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent10.2214/ajr.142.3.619 ↗
15. Sensitivity and power deposition in a high-field imaging experiment10.1002/1522-2586(200007)12:1<46::AID-JMRI6>3.0.CO;2-D ↗
16. “High Resolution X-ray Computed Tomography: an Emerging Tool for Small Animal Cancer Research|Elsevier Enhanced Reader.” [Online]. Available: https://reader.elsevier.com/reader/sd/pii/S1476558600800214?token=A5BCDA4933B6AF05E6BB02C7334B5D1101B3184F61CBAD3124F22035B6B773779C141B105C816684AE2FD7B721F0D765. (Accessed 06 September 2020).
17. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer10.1001/archinternmed.2009.427 ↗
18. Medical radiation exposure IN the U.S. IN 2006: preliminary results10.1097/01.HP.0000326333.42287.a2 ↗
19. New technologies for human cancer imaging10.1200/JCO.2007.14.3065 ↗
20. Contrast-enhanced ultrasound imaging of prostate cancer
21. Positron emission tomography and leiomyomas: clinicopathologic analysis of 3 cases of PET scan-positive leiomyomas and literature review10.1016/j.ygyno.2006.09.024 ↗
22. The utility of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in the investigation of patients with disseminated carcinoma of unknown primary origin10.1007/s11307-005-4114-x ↗
23. Imaging and cancer: a review10.1016/j.molonc.2008.04.001 ↗
24. Evolving role of positron emission tomography in breast cancer imaging10.1053/j.semnuclmed.2004.11.001 ↗
25. “Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin’s lymphomas10.1016/j.rcl.2004.08.008 ↗
26. Molecular tracers for the PET and SPECT imaging of disease10.1039/B922628C ↗
27. Fluorescence molecular tomography: principles and potential for pharmaceutical research10.3390/pharmaceutics3020229 ↗
28. Fluorescence molecular imaging of small animal tumor models macrophage and microglia mediated immunotherapy view project10.2174/1566524043360555 ↗
29. Fluorescence molecular imaging of small animal tumor models fluorescence molecular imaging of small animal tumor models10.2174/1566524043360555 ↗
30. Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging10.1038/sj.neo.7900121 ↗
31. Using in vivo bioluminescence imaging to shed light on cancer biology10.1109/JPROC.2005.844261 ↗
32. A practical guide on imaging intracellular structures in live animals Intravital microscopy10.4161/bioa.21758 ↗
33. Intravital imaging10.1016/j.cell.2011.11.004 ↗
34. Intravital microscopy of osteolytic progression and therapy response of cancer lesions in the bone10.1126/scitranslmed.aao5726 ↗
35. Multiphoton intravital microscopy of mandibular draining lymph nodes: a mouse model to study corneal immune responses10.3389/fimmu.2020.00039 ↗
36. Intravital multiphoton microscopy as a novel tool in the field of immunopharmacology10.1016/j.pharmthera.2019.107429 ↗
37. Vici: in vivo molecular imaging of immune response10.1016/j.immuni.2007.10.006 ↗
38. The immunoimaging toolbox10.2967/jnumed.116.185967 ↗
39. Biomarkers and molecular probes for cell death imaging and targeted therapeutics10.1021/bc3003309 ↗
40. A molecular imaging primer: modalities, imaging agents, and applications10.1152/physrev.00049.2010 ↗
41. PTK7: a new biomarker for immunophenotypic characterization of maturing T cells and T cell acute lymphoblastic leukemia10.1016/j.leukres.2012.07.004 ↗
42. Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells10.1038/gt.2011.206 ↗
43. Advances in imaging probes and optical microendoscopic imaging techniques for early in vivo cancer assessment10.1016/j.addr.2013.09.012 ↗
44. Antibody engineering for pursuing a healthier future10.3389/fmicb.2017.00495 ↗
45. Aptamers selected for higher-affinity binding are not more specific for the target ligand10.1021/ja060952q ↗
46. Reporter gene imaging10.2214/AJR.13.10555 ↗
47. Advancing immune and cell-based therapies through imaging10.1007/s11307-017-1069-7 ↗
48. Imaging of human lymph nodes using optical coherence tomography: potential for staging cancer10.1158/0008-5472.CAN-09-4062 ↗
49. Nguyen · 2009
50. Optical coherence tomography: the intraoperative assessment of lymph nodes in breast cancer10.1109/MEMB.2009.935722 ↗
51. Molecular imaging with optical coherence tomography using ligand-conjugated microparticles that detect activated endothelial cells: rational design through target quantification10.1016/j.atherosclerosis.2011.07.127 ↗
52. Detection of ultrawide-band ultrasound pulses in optoacoustic tomography10.1109/TUFFC.2003.1244756 ↗
53. Noninvasive laser-induced photoacoustic tomography for structural and functional in vivo imaging of the brain10.1038/nbt839 ↗
54. Backward-mode multiwavelength photoacoustic scanner using a planar Fabry-Perot polymer film ultrasound sensor for high-resolution three-dimensional imaging of biological tissues10.1364/AO.47.000561 ↗
55. Photoacoustic imaging of early inflammatory response using gold nanorods10.1063/1.2743752 ↗
56. Two-photon imaging of lymphocyte motility and antigen response in intact lymph node10.1126/science.1070051 ↗
57. Mougiakakos · 2010
58. Imaging regulatory T cell dynamics and CTLA4-mediated suppression of T cell priming10.1038/ncomms7219 ↗
59. Efficient Treg depletion induces T-cell infiltration and rejection of large tumors10.1002/eji.201041093 ↗
60. Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation10.1016/j.immuni.2006.04.015 ↗
61. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis10.1038/bjc.2011.189 ↗
62. Immune infiltration in human tumors: a prognostic factor that should not be ignored10.1038/onc.2009.416 ↗
63. An effective immuno-PET imaging method to monitor CD8-dependent responses to immunotherapy10.1158/0008-5472.CAN-15-1707 ↗
64. Imaging activated T cells predicts response to cancer vaccines10.1172/JCI98509 ↗
65. Principles of Immunophenotyping
66. Multiplexed ion beam imaging of human breast tumors10.1038/nm.3488 ↗
67. A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging10.1016/j.cell.2018.08.039 ↗
68. Molecular imaging of tumor-infiltrating macrophages in a preclinical mouse model of breast cancer10.7150/thno.11546 ↗
69. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages10.1158/0008-5472.CAN-11-2994 ↗
70. Imaging and characterization of macrophage distribution in mouse models of human prostate cancer10.1007/s11307-019-01318-5 ↗
71. Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer10.1158/2159-8290.CD-14-0621 ↗
72. The folate receptor β as a macrophage-mediated imaging and therapeutic target in rheumatoid arthritis10.1007/s13346-018-0589-2 ↗
73. Nanoscale imaging and mechanical analysis of Fc receptor-mediated macrophage phagocytosis against cancer cells10.1021/la4042524 ↗
74. Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines10.1002/ijc.22385 ↗
75. A novel 19F agent for detection and quantification of human dendritic cells using magnetic resonance imaging10.1002/ijc.25672 ↗
76. Dendritic cells: therapy and imaging10.1517/14712590902867739 ↗
77. Monitoring T cell-dendritic cell interactions in vivo by intercellular enzymatic labelling10.1038/nature25442 ↗
78. Nanomedicine for cancer diagnosis and therapy: advancement, success and structure-activity relationship10.4155/tde-2017-0062 ↗
79. Nanostructured lipid carriers employing polyphenols as promising anticancer agents: quality by design (QbD) approach10.1016/j.ijpharm.2017.04.078 ↗
80. Nano-engineered delivery systems for cancer imaging and therapy: recent advances, future direction and patent evaluation10.1016/j.drudis.2018.08.009 ↗
81. Nanomedicine for cancer immunotherapy: tracking cancer-specific T-cells in vivo with gold nanoparticles and CT imaging10.1021/acsnano.5b01939 ↗
82. PET imaging of tumor-associated macrophages with 89Zr-labeled high-density lipoprotein nanoparticles10.2967/jnumed.115.158956 ↗
83. Monitoring innate immune cell dynamics in the glioma microenvironment by magnetic resonance imaging and multiphoton microscopy (MR-MPM)10.7150/thno.38659 ↗
84. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome10.3389/fphar.2017.00561 ↗
85. Single-Cell Transcriptome Analysis in Tumor Tissues
86. Immune checkpoint blockade: a common denominator approach to cancer therapy10.1016/j.ccell.2015.03.001 ↗
87. Relevance of tumor-infiltrating lymphocytes in breast cancer10.1186/s12916-015-0431-3 ↗
88. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis10.1038/s41591-018-0078-7 ↗
89. Immune cell dynamics unfolded by single-cell technologies10.3389/fimmu.2018.01435 ↗
90. Unraveling cell populations in tumors by single-cell mass cytometry10.1016/j.copbio.2014.07.004 ↗
91. Imaging Mass Cytometry10.1002/cyto.a.23053 ↗
92. Multiplexed epitope-based tissue imaging for discovery and healthcare applications10.1016/j.cels.2016.03.008 ↗
93. Biodistribution of cisplatin revealed by imaging mass cytometry identifies extensive collagen binding in tumor and normal tissues10.1038/srep36641 ↗
94. Highly multiplexed imaging mass cytometry allows visualization of tumor and immune cell interactions of the tumor microenvironment in FFPE tissue sections
95. Multiplex protein detection on circulating tumor cells from liquid biopsies using imaging mass cytometry10.1088/2057-1739/aaa013 ↗
96. Larbi · 2020
97. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma10.1126/science.1254257 ↗
98. Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer10.1038/ncomms15081 ↗
99. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment10.1016/j.cell.2018.05.060 ↗
100. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq10.1126/science.aad0501 ↗